SynthesisEuropean heart journal. Cardiovascular pharmacotherapy2023
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease.
Synthesis in European heart journal. Cardiovascular pharmacotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- [Efficacy and safety of dual anti-platelet aggregation short post-pharmacologic stent].Revista medica del Instituto Mexicano del Seguro Social · 2026Pooled it
- 'Aspirin versus ticagrelor for the management after coronary revascularization - a systematic review and meta‑analysis of randomised trials'.BMC cardiovascular disorders · 2026Pooled it
- Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2025Pooled it
- P2YBMJ (Clinical research ed.) · 2025Pooled it
- Comparative Efficacy and Safety of Different Low-Dose Platelet Inhibitors in Patients With Coronary Heart Disease: A Bayesian Network Meta-Analysis.Journal of evidence-based medicine · 2024Pooled it
- Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study.Arteriosclerosis, thrombosis, and vascular biology · 2025Trial
- The evolution of dual antiplatelet therapy in patients with coronary artery disease.European heart journal open · 2026Article
- MicroRNA-223-3p is a determinant of platelet procoagulant activity.Blood advances · 2026Article
- Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI.Journal of thrombosis and thrombolysis · 2026Article
- Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- Article
- Entering a new era of antiplatelet therapy: the 4D-ACS trial.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- Insights on DAPT Abbreviation and De-escalation from ULTIMATE-DAPT and Related Trials: Are we Heading Toward an Aspirin-Free Strategy?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Article
- Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease: 2025 Update.JACC. Asia · 2025Review
- One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Treatment of non-ST-segment elevation myocardial infarction in the elderly: the SENIOR-RITA trial.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Editorial: Short and long-term treatment options in patients with acute coronary syndrome.Frontiers in cardiovascular medicine · 2025Article
- Clopidogrel: Drug of the Past or Drug of the Future?Cardiovascular drugs and therapy · 2024Article
- Antiplatelet therapy in elderly patients with ACS: moving targets need more tailored treatments.Journal of thrombosis and thrombolysis · 2024Article
- Individualising Antithrombotic Strategies for Acute and Chronic Coronary Syndromes.Interventional cardiology (London, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 20 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple guidelines and consensus papers have addressed the role of antithrombotic strategies in patients with established coronary artery disease (CAD). Since evidence and terminology continue to evolve, the authors undertook a consensus initiative to guide clinicians to select the optimal antithrombotic regimen for each patient. The aim of this document is to provide an update for clinicians on best antithrombotic strategies in patients with established CAD, classifying each treatment option in relation to the number of antithrombotic drugs irrespective of whether the traditional mechanism of action is expected to mainly inhibit platelets or coagulation cascade. With the aim to reach comprehensiveness of available evidence, we systematically reviewed and performed meta-analyses by means of both direct and indirect comparisons to inform the present consensus document.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.